title: Effects of intravenous amiodarone and ibutilide on action potential duration and atrial conduction kinetics in patients with persistent atrial fibrillation.
abstract: Class III antiarrhythmic drugs have been shown to be effective for termination of atrial fibrillation (AF). The aim of this study was to determine the steady state and non-steady state effects of amiodarone and ibutilide on the atrial monophasic action potential (MAP) duration (MAPD), effective refractory period (ERP), and intra-atrial conduction time (IACT) in human persistent AF.Fourteen patients with persistent AF who underwent internal atrial defibrillation were included in the study. The atrial MAP was recorded at the high right atrium. IACT was measured from the pacing spike to the distal coronary sinus. MAPD and IACT were assessed during the steady state and at the shortest diastolic interval (DI) at a basic cycle length (CL) of 600 msec and after a premature stimulus. Amiodarone did not affect MAPD or the ERP at the basic CL, but it increased MAPD at the shortest DI. Amiodarone increased IACT at both the basic CL and the shortest DI. Ibutilide increased the MAPD and ERP at the basic CL and at the shortest DI. Ibutilide did not affect IACT at the basic CL or the shortest DI.Ibutilide increases atrial MAPD not only in the steady state but also at the shortest DI, but it does not affect IACT in patients with persistent AF. Amiodarone does not affect MAPD or ERP, but it increases IACT in the steady state, and it increases MAPD and IACT at the shortest DI.
authors.affiliation: Division of Cardiology, Department of Medicine, Nihon University School of Medicine.
authors.forename: Naoko
authors.initials: N
authors.lastname: Sasaki
authors.forename: Ichiro
authors.initials: I
authors.lastname: Watanabe
authors.forename: Rikitake
authors.initials: R
authors.lastname: Kogawa
authors.forename: Kazumasa
authors.initials: K
authors.lastname: Sonoda
authors.forename: Keiko
authors.initials: K
authors.lastname: Takahashi
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Okumura
authors.forename: Kimie
authors.initials: K
authors.lastname: Ohkubo
authors.forename: Toshiko
authors.initials: T
authors.lastname: Nakai
authors.forename: Atsushi
authors.initials: A
authors.lastname: Hirayama
mesh_terms: D000200:Action Potentials / Q000187:drug effects; D000328:Adult; D000368:Aged; D000638:Amiodarone / Q000008:administration & dosage*; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D004562:Electrocardiography / Q000187:drug effects*; D005260:Female; D005500:Follow-Up Studies; D006325:Heart Atria / Q000503:physiopathology*; D006329:Heart Conduction System / Q000187:drug effects / Q000503:physiopathology*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D013449:Sulfonamides / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D000889:Anti-Arrhythmia Agents; D013449:Sulfonamides; C067192:ibutilide; D000638:Amiodarone